Growth Metrics

Biogen (BIIB) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $29.4 billion.

  • Biogen's Liabilities and Shareholders Equity rose 495.63% to $29.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $115.0 billion, marking a year-over-year increase of 480.81%. This contributed to the annual value of $29.4 billion for FY2025, which is 495.63% up from last year.
  • Biogen's Liabilities and Shareholders Equity amounted to $29.4 billion in Q4 2025, which was up 495.63% from $29.2 billion recorded in Q3 2025.
  • In the past 5 years, Biogen's Liabilities and Shareholders Equity ranged from a high of $29.4 billion in Q4 2025 and a low of $23.6 billion during Q1 2022
  • In the last 5 years, Biogen's Liabilities and Shareholders Equity had a median value of $25.9 billion in 2023 and averaged $26.2 billion.
  • In the last 5 years, Biogen's Liabilities and Shareholders Equity tumbled by 866.99% in 2021 and then surged by 1343.43% in 2023.
  • Over the past 5 years, Biogen's Liabilities and Shareholders Equity (Quarter) stood at $23.9 billion in 2021, then increased by 2.83% to $24.6 billion in 2022, then grew by 9.33% to $26.8 billion in 2023, then rose by 4.49% to $28.0 billion in 2024, then grew by 4.96% to $29.4 billion in 2025.
  • Its last three reported values are $29.4 billion in Q4 2025, $29.2 billion for Q3 2025, and $28.3 billion during Q2 2025.